FDA to review generic blood-pressure med

Share this article:

FDA plans to study generic copies of AstraZeneca's extended-release blood pressure medication Toprol XL (metroprolol succinate), amid 3,424 adverse-incident reports made against the drugs.

Those AE reports cite “a lack of effectiveness and troublesome side effects,” reports Bloomberg, which analyzed them.

According to the news service, FDA will assess whether the copies are chemically the same as the original, as noted in a funding request made by the agency.

The generic copies in question are manufactured by Wockhardt Ltd. and Dr. Reddy's Laboratories, both of which are based in India, and by US-based Mylan and Actavis.

The effort to evaluate metoprolol succinate broadens on a $20-million FDA testing program begun in September, Bloomberg points out, and follows criticism of the agency's handling of generics made overseas and distributed domestically.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.